BioProspect cops Euro setback
Friday, 01 July, 2005
Brisbane natural pesticide developer BioProspect (ASX:BPO) faced a setback this week, after its potential European licensee, Germany's W Neudorff, declined to pursue development of BioProspect's eucalyptus-derived biocide for carpet beetles and clothes moths.
Neudorff cited concerns about the estimated cost of manufacturing and registering a formulated Qcide product for Germany and Europe.
Only three months ago, BioProspect received a similar knockback from another potential partner, Sumitomo Australia. At the time, Bioprospect said the Neudorff trials were "progressing very well".
In the wake of thefailed deal, the company said it was continuing with other confidential evaluation agreements in Australia and the US for the consumer goods and animal markets.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
